Royce & Associates’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.04M | Buy |
305,812
+3,210
| +1% | +$94.9K | 0.09% | 314 |
|
|
2025
Q1 | $9.03M | Sell |
302,602
-36,927
| -11% | -$1.1M | 0.1% | 309 |
|
|
2024
Q4 | $9.73M | Buy |
339,529
+33,674
| +11% | +$965K | 0.09% | 330 |
|
|
2024
Q3 | $11.8M | Buy |
305,855
+4,966
| +2% | +$192K | 0.11% | 274 |
|
|
2024
Q2 | $9.69M | Buy |
300,889
+12,180
| +4% | +$392K | 0.09% | 319 |
|
|
2024
Q1 | $11.2M | Buy |
288,709
+145,626
| +102% | +$5.65M | 0.1% | 295 |
|
|
2023
Q4 | $4.4M | Buy |
143,083
+121,853
| +574% | +$3.75M | 0.04% | 518 |
|
|
2023
Q3 | $474K | Buy |
+21,230
| New | +$474K | ﹤0.01% | 818 |
|
|
2023
Q1 | – | Sell |
-14,477
| Closed | -$336K | – | 919 |
|
|
2022
Q4 | $336K | Sell |
14,477
-13,843
| -49% | -$321K | ﹤0.01% | 858 |
|
|
2022
Q3 | $454K | Sell |
28,320
-431,923
| -94% | -$6.92M | 0.01% | 829 |
|
|
2022
Q2 | $8.16M | Buy |
460,243
+168,989
| +58% | +$2.99M | 0.08% | 341 |
|
|
2022
Q1 | $5.93M | Sell |
291,254
-32,632
| -10% | -$664K | 0.05% | 512 |
|
|
2021
Q4 | $6.05M | Buy |
323,886
+148,377
| +85% | +$2.77M | 0.05% | 519 |
|
|
2021
Q3 | $3.47M | Buy |
+175,509
| New | +$3.47M | 0.03% | 654 |
|
|
2020
Q1 | – | Sell |
-1,421
| Closed | -$29K | – | 1157 |
|
|
2019
Q4 | $29K | Sell |
1,421
-1,060
| -43% | -$21.6K | ﹤0.01% | 1085 |
|
|
2019
Q3 | $28K | Buy |
2,481
+1,013
| +69% | +$11.4K | ﹤0.01% | 1100 |
|
|
2019
Q2 | $19K | Buy |
1,468
+373
| +34% | +$4.83K | ﹤0.01% | 1117 |
|
|
2019
Q1 | $17K | Buy |
+1,095
| New | +$17K | ﹤0.01% | 1131 |
|
|
2018
Q3 | – | Sell |
-138,000
| Closed | -$3.29M | – | 1185 |
|
|
2018
Q2 | $3.29M | Sell |
138,000
-32,000
| -19% | -$763K | 0.02% | 710 |
|
|
2018
Q1 | $4.34M | Buy |
170,000
+33,000
| +24% | +$843K | 0.03% | 613 |
|
|
2017
Q4 | $2.53M | Buy |
+137,000
| New | +$2.53M | 0.02% | 791 |
|